West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$302.78 USD
+2.26 (0.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $302.74 -0.04 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$302.78 USD
+2.26 (0.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $302.74 -0.04 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth D Momentum F VGM
Zacks News
STERIS (STE) Q1 Earnings Beat Estimates, 2022 Guidance Up
by Zacks Equity Research
STERIS (STE) reported better-than-expected revenues for first-quarter fiscal 2022 on strong segmental performance driving the top line.
ShockWave Medical (SWAV) Q2 Earnings, Revenues Top Estimates
by Zacks Equity Research
ShockWave Medical's (SWAV) robust performance across product lines and geographies drive its Q2 sales.
SmileDirectClub (SDC) Q2 Loss Wider Than Expected, Margin Up
by Zacks Equity Research
SmileDirectClub (SDC) registered year-over-year revenue growth in the second quarter, driven primarily by unique aligner shipment.
Syneos Health (SYNH) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Syneos Health (SYNH) reported better-than-expected revenues for the second quarter of 2021 on strong segmental performance.
Allscripts' (MDRX) Shares Up Following Q2 Earnings Beat
by Zacks Equity Research
Allscripts' (MDRX) robust Q2 results demonstrate its strength in Client services segment.
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.
Glaukos (GKOS) Stock Gains 0.1% Following Lower Loss in Q2
by Zacks Equity Research
Despite reporting second-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.
AMN Healthcare (AMN) Q2 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.
Nevro (NVRO) Q2 Earnings Surpass Estimates, Revenues Lag
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues rise on a year-over-year basis in Q2 despite pandemic-led business challenges.
Quidel (QDEL) Q2 Earnings Fall Shy of Estimates, Margins Down
by Zacks Equity Research
Quidel's (QDEL) dismal Q2 performance stems from lower revenues across majority of its product categories.
Illumina (ILMN) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Year-over-year improvement in segmental revenues in Q2 across all geographies exceeds Illumina's (ILMN) expectations.
Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio
by Zacks Equity Research
Strong performance by the Dental, Medical & Technology and Value-Added Services segments is driving Henry Schein's (HSIC) top line.
ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Increased demand for sleep devices and masks, including recovery of core sleep patient flow, drove ResMed's (RMD) fiscal fourth-quarter growth.
Insulet (PODD) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Insulet (PODD) reports better-than-expected revenues for second-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.
Inogen (INGN) Stock Loses 26.7% In Spite of Q2 Earnings Beat
by Zacks Equity Research
Inogen's (INGN) second-quarter results benefit from higher revenues across its segments.
LHC Group (LHCG) Stock Loses 11.9% Despite Q2 Earnings Beat
by Zacks Equity Research
LHC Group's (LHCG) second-quarter results benefit from organic growth in both home health and hospice admissions.
Is West Pharmaceutical (WST) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
West Pharmaceutical (WST) possesses solid growth attributes, which could help it handily outperform the market.
Abiomed's (ABMD) Q1 Earnings and Revenues Beat, Margins Up
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
Here's Why West Pharmaceutical Services (WST) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does West Pharmaceutical Services (WST) have what it takes to be a top stock pick for momentum investors? Let's find out.
BD (BDX) Beats on Q3 Earnings and Revenues, Ups '21 View
by Zacks Equity Research
Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal third quarter, thus driving up the overall top line.
Surmodics' (SRDX) Q3 Earnings, Revenues Fall Shy of Estimates
by Zacks Equity Research
Higher revenues from the IVD segment drives Surmodics' (SRDX) fiscal third-quarter top line.
Tandem Diabetes (TNDM) Q2 Earnings Rise Y/Y, Sales View Up
by Zacks Equity Research
Tandem Diabetes (TNDM) reports better-than-expected revenues for second quarter 2021 on strong domestic and international pump shipments driving the top line.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Grow
by Zacks Equity Research
Amedisys (AMED) reports better-than-expected earnings for the second quarter with strong performance in Home Health and Hospice segments.
Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected
by Zacks Equity Research
Strength in both coronary and peripheral segments drove Cardiovascular Systems' (CSII) revenues in the fiscal fourth quarter.
Globus Medical (GMED) Q2 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Pull-through from robotics, contributions from new product introductions and resurgence in the Globus Medical's (GMED) biologics business drove second-quarter growth.